Some types of human papillomavirus (HPV), the most common sexually transmitted viral infection, are high risk and can cause cervical cancer. Screening options for the prevention and early detection of cervical cancer depend on the age of the individual and may include cytology, cotesting, and primary high-risk HPV (hrHPV) testing. For individuals 25 to 30 years of age with a cervix, two recommended cervical cancer screening options are available: primary hrHPV testing or cytology.
Refer to ARUP Laboratories’ test offerings below.
ARUP Laboratory Tests
Qualitative Polymerase Chain Reaction
Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by Nucleic Acid Amplification (NAA), ThinPrep 3003005
Qualitative Nucleic Acid Amplification (NAA)